Status:
COMPLETED
Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Gram-Positive Bacterial Infections
Escherichia Coli Infections
Eligibility:
All Genders
15+ years
Brief Summary
To determine the value of increasing use of piperacillin/tazobactam as empiric therapy and restricting extended-spectrum cephalosporins in reducing the cases of ESBL producing Escherichia coli and Kle...
Eligibility Criteria
Inclusion
- Eligible patients of either sex, 15 years of age or older
- Patients who are admitted to the department of hematology and oncology
- Provide written informed consent
Exclusion
- Patients who have hypersensitivity to β-lactam antibiotics
- Female who are pregnant or breast-feeding
- Any underlying conditions or non-infectious diseases that will be ultimately fatal within 30 days
Key Trial Info
Start Date :
February 1 2005
Trial Type :
OBSERVATIONAL
End Date :
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT00167999
Start Date
February 1 2005
Last Update
March 15 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul, South Korea, 133-792